SLS · Sellas Life Sciences Group, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $1.00M | $7.60M | $1.90M |
| Cost of Revenue | $0 | $0 | $0 | $100.0K | $0 | - |
| Gross Profit | - | - | $0 | $900.0K | $7.60M | - |
| R&D | $16.02M | $19.10M | $24.01M | $15.67M | $15.67M | $9.28M |
| SG&A | $12.25M | $12.42M | $13.86M | $12.58M | $11.32M | $9.60M |
| Total Operating Expenses | $28.27M | $31.51M | $37.87M | $42.95M | $32.89M | $18.88M |
| D&A | - | - | - | - | - | - |
| Operating Income | ($28.27M) | ($31.51M) | ($37.87M) | ($41.95M) | ($25.29M) | ($16.98M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | $0 | ($237.0K) | ($17.0K) |
| Net Income | ($26.86M) | ($30.88M) | ($37.34M) | ($41.30M) | ($20.70M) | ($16.76M) |
| EPS - Basic | ($0.25) | ($0.50) | ($1.34) | ($2.13) | ($2.11) | - |
| EPS - Diluted | ($0.25) | ($0.50) | ($1.34) | ($2.13) | ($2.11) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $71.79M | $13.89M | $2.53M | $17.13M | $21.36M | $35.30M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $2.95M | $3.50M | $5.64M | $3.36M | $2.14M | $4.66M |
| Current Assets | $75.21M | $16.33M | $3.17M | $17.76M | $23.04M | $36.92M |
| Total Assets | $78.34M | $19.43M | $6.22M | $20.94M | $26.27M | $46.05M |
| Current Liabilities | $7.02M | $9.51M | $13.73M | $15.52M | $4.98M | $12.34M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $7.47M | $9.97M | $14.20M | $16.09M | $5.93M | $18.09M |
| Stockholders' Equity | $70.87M | $9.46M | ($7.98M) | $4.85M | $20.35M | $27.96M |
| Retained Earnings | ($274.99M) | ($248.13M) | ($217.24M) | ($179.90M) | ($138.60M) | ($117.90M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($28.39M) | ($35.40M) | ($31.41M) | ($23.81M) | ($26.02M) | ($10.42M) |
| Investing Cash Flow | - | $0 | ($5.50M) | $0 | - | - |
| Financing Cash Flow | $86.30M | $46.76M | $22.32M | $24.08M | $12.07M | $38.44M |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | 90.0% | 100.0% | - |
| Operating margin | - | - | - | -4195.0% | -332.8% | -893.8% |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | -4130.1% | -272.4% | -881.9% |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | 1567.4% | 206.2% | 488.5% |
| SG&A / Revenue | - | - | - | 1258.2% | 148.9% | 505.3% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -34.3% | -158.9% | -600.4% | -197.2% | -78.8% | -36.4% |
| Return on equity | -37.9% | -326.3% | 468.2% | -851.4% | -101.7% | -59.9% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 10.72 | 1.72 | 0.23 | 1.14 | 4.63 | 2.99 |
| Quick ratio | 10.72 | 1.72 | 0.23 | 1.14 | 4.63 | 2.99 |
| Cash ratio | 10.23 | 1.46 | 0.18 | 1.10 | 4.29 | 2.86 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.11 | 2.05 | -0.78 | 4.32 | 1.29 | 1.65 |
| Liabilities / Assets | 0.10 | 0.51 | 2.28 | 0.77 | 0.23 | 0.39 |
| Efficiency | ||||||
| Asset turnover | - | - | 0.00 | 0.05 | 0.29 | 0.04 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | 12253d | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 5.8x | 6.7x | - | 9.4x | 2.2x | - |
| P / S | - | - | - | 45.8x | 5.8x | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | -100.0% | -86.8% | 300.0% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | -88.2% | - | - |
| Operating income growth (YoY) | 10.3% | 16.8% | 9.7% | -65.8% | -48.9% | 12.3% |
| Net income growth (YoY) | 13.0% | 17.3% | 9.6% | -99.5% | -23.5% | 13.1% |
| EPS growth (YoY) | 50.0% | 62.7% | 37.1% | -0.9% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 648.8% | - | - | -76.2% | -27.2% | 358.9% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing SELLAS Life Sciences Group against the 5 most active filers in the same SIC group.